Drug-Induced Hypersensitivity: Mechanisms, Risk Factors, and Management Strategies

Ms. Shakila S. Shaikh[1], Mr. Mahesh Subhash Thange[2], Dr. Ganesh Bhagwat Giri[3], Ms. Varsha Mahavir Dhulasavant[4], Mrs.Shinde Punam Madhukar[5], Mr Vasim Mansur Aparadh[6]
[1]RJSPM's College Of Pharmacy, [2]Samarth College Of Pharmacy, Belhe,Junnar, Pune, [3]Sbspm's B. Pharmacy College Ambajogai, [4]Dr.J.J.Magdum College Of Pharmacy Jaysingpur Wadi Road Jaysingpure , [5]P.V. Belhekar College Of Pharmacy Bhanashiware, [6]Y.D.Mane Institute Of Pharmacy Kagal

***Abstract*—Drug-induced hypersensitivity (DIH) is an adverse immune-mediated reaction to pharmaceutical agents, posing significant challenges in clinical practice. These reactions range from mild skin rashes to severe conditions such as anaphylaxis, Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN). The underlying mechanisms of DIH involve both immunological pathways—classified under Type I to Type IV hypersensitivity—and non-immunologic reactions. Genetic predisposition, drug metabolism, environmental factors, and previous drug exposures contribute to the risk of developing hypersensitivity. Several drug classes, including antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, and biologics, are commonly implicated in hypersensitivity reactions. Diagnosis relies on clinical presentation, laboratory investigations, skin testing, and in vitro assays. Management strategies involve immediate drug discontinuation, symptomatic treatment, desensitization protocols, and alternative medication selection. Advances in pharmacogenomics hold promise for personalized medicine, enabling predictive screening to minimize adverse drug reactions. This review comprehensively explores the pathophysiology, risk factors, diagnostic approaches, and management strategies for drug-induced hypersensitivity, highlighting emerging trends and future directions in hypersensitivity prevention and treatment.**

***Index Terms*—Drug-induced hypersensitivity, adverse drug reactions, immune-mediated reactions, pharmacogenomics, desensitization, risk factors, management strategies.**

I. INTRODUCTION

Drug-induced hypersensitivity (DIH) refers to an adverse immune-mediated reaction triggered by pharmaceutical agents, affecting various organ systems and leading to significant morbidity and mortality. These reactions can range from mild allergic responses, such as skin rashes and pruritus, to severe life-threatening conditions, including anaphylaxis, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS). Hypersensitivity reactions can occur unpredictably, posing challenges in clinical diagnosis and management.

The pathophysiology of DIH involves complex immunological and non-immunologic mechanisms. Classical immune-mediated hypersensitivity reactions are categorized under the Gell and Coombs classification as Type I (IgE-mediated), Type II (cytotoxic), Type III (immune complex-mediated), and Type IV (T-cell-mediated delayed hypersensitivity). In addition, non-immunologic mechanisms, such as direct mast cell activation and metabolic idiosyncrasies, can also contribute to hypersensitivity responses.

Multiple factors influence an individual's susceptibility to drug hypersensitivity, including genetic predisposition, metabolic variations, prior drug exposure, comorbidities, and environmental influences. Certain drug classes, such as β-lactam antibiotics, nonsteroidal anti-inflammatory drugs (NSAIDs), anticonvulsants, and biologic agents, are frequently implicated in hypersensitivity reactions. The clinical presentation varies widely, necessitating a multidisciplinary approach to accurate diagnosis and effective management.

Early recognition and appropriate intervention are crucial to minimizing complications associated with DIH. Current management strategies involve drug

discontinuation, symptomatic treatment with antihistamines and corticosteroids, desensitization protocols, and alternative drug selection. Advances in pharmacogenomics have opened new avenues for predicting hypersensitivity reactions and personalizing drug therapy to enhance patient safety.

This review provides a comprehensive analysis of drug-induced hypersensitivity, focusing on its immunopathogenesis, risk factors, commonly implicated drugs, diagnostic approaches, and management strategies. Furthermore, emerging trends in pharmacogenetics and preventive strategies are discussed to highlight future directions in hypersensitivity research and clinical practice.

II. MECHANISMS OF DRUG-INDUCED HYPERSENSITIVITY

Here's a detailed section on "Mechanisms of Drug-Induced Hypersensitivity" for your review paper.

Drug-induced hypersensitivity (DIH) reactions can be broadly categorized into immunological and non-immunologic mechanisms. The adaptive immune system mediates immunological hypersensitivity reactions, whereas non-immunologic mechanisms involve direct drug interactions with immune cells without prior sensitization.

2.1 Immunological Pathways

The immunological mechanisms of DIH follow the Gell and Coombs classification, which includes four types of hypersensitivity reactions:

2.1.1 Type I Hypersensitivity (IgE-Mediated, Anaphylaxis)

- Mechanism: Type I reactions occur when a drug acts as an allergen, triggering the production of IgE antibodies that bind to mast cells and basophils. Upon re-exposure, antigen cross-linking induces histamine release, leading to allergic reactions.
- Clinical Manifestations:
  - Urticaria, angioedema
  - Bronchospasm
  - Hypotension, anaphylaxis
- Examples:
  - Penicillins, cephalosporins
  - NSAIDs
  - Monoclonal antibodies (e.g., rituximab, infliximab)

2.1.2 Type II Hypersensitivity (Cytotoxic Reactions)

- Mechanism: IgG or IgM antibodies bind to drug-modified host cells in Type II hypersensitivity, leading to complement activation and cell lysis.
- Clinical Manifestations:
  - Hemolytic anemia (destruction of red blood cells)
  - Thrombocytopenia (low platelet count)
  - Neutropenia (reduced neutrophils)
- Examples:
  - Methyldopa, penicillins (inducing autoimmune hemolytic anemia)
  - Quinidine, heparin (causing thrombocytopenia)

2.1.3 Type III Hypersensitivity (Immune Complex-Mediated Reactions)

- Mechanism: Drug-antibody immune complexes are deposited in tissues, activating the complement system and causing inflammatory damage.
- Clinical Manifestations:
  - Serum sickness-like syndrome (fever, rash, joint pain)
  - Vasculitis
  - Glomerulonephritis
- Examples:
  - Sulfonamides, hydralazine (drug-induced lupus)
  - Phenytoin, allopurinol (serum sickness)

2.1.4 Type IV Hypersensitivity (Delayed, T-Cell Mediated)

- Mechanism: Type IV hypersensitivity is mediated by T lymphocytes rather than antibodies. These reactions are typically delayed (48–72 hours) and can lead to severe cutaneous and systemic disorders.
- Clinical Manifestations:
  - Contact dermatitis
  - Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)
  - Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
- Examples:
  - Carbamazepine, allopurinol, sulfonamides (SJS/TEN)
  - Tuberculosis drugs (isoniazid, rifampin) (contact dermatitis)

2.2 Non-Immunologic Mechanisms

Non-immunologic drug hypersensitivity reactions mimic allergic responses but do not involve antigen-

specific immune activation. Instead, they occur due to direct pharmacological effects on immune cells.

2.2.1 Pseudoallergic Reactions

- Mechanism: Direct activation of mast cells and basophils leads to histamine release without IgE involvement.
- Clinical Manifestations:
  - Similar to Type I hypersensitivity (urticaria, bronchospasm, hypotension)
- Examples:
  - Radiocontrast media (used in CT scans)
  - Opioids (morphine-induced histamine release)
  - Vancomycin (Red Man Syndrome)

2.2.2 Pharmacologic Interaction with Immune Receptors (P-I Concept)

- Mechanism: Drugs bind directly to T-cell receptors (TCRs) or HLA molecules, bypassing antigen presentation pathways.
- Examples:
  - Abacavir hypersensitivity (HLA-B*57:01)
  - Carbamazepine hypersensitivity (HLA-B*15:02, associated with SJS/TEN in Asian populations)

III. RISK FACTORS

Drug-induced hypersensitivity (DIH) is influenced by multiple factors, including genetic predisposition, drug properties, patient-specific characteristics, and environmental influences. Understanding these risk factors is crucial for predicting and preventing hypersensitivity reactions.

3.1 Genetic Predisposition

Genetic variability plays a critical role in an individual's susceptibility to drug hypersensitivity. Specific human leukocyte antigen (HLA) alleles and drug-metabolizing enzyme polymorphisms have been associated with severe hypersensitivity reactions.

HLA Associations: Certain HLA alleles are strongly linked to hypersensitivity reactions:

- HLA-B*57:01 – Abacavir hypersensitivity syndrome
- HLA-B*15:02 – Carbamazepine-induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)
- HLA-A*31:01 – Carbamazepine-induced delayed hypersensitivity reactions
- HLA-B*58:01 – Allopurinol-induced SJS/TEN

Polymorphisms in Drug-Metabolizing Enzymes:

- CYP2C9 variants – Altered metabolism of NSAIDs and phenytoin, increasing hypersensitivity risk
- NAT2 polymorphisms – Linked to sulfonamide hypersensitivity
- UDP-glucuronosyltransferase (UGT1A1) mutations – Associated with irinotecan-induced toxicity

3.2 Drug Properties

The chemical structure, metabolism, and immune-stimulating potential of a drug contribute to its hypersensitivity risk.

High Reactivity and Metabolism: Drugs that undergo bioactivation to reactive metabolites are more likely to trigger immune responses.

- Sulfonamides – Form reactive metabolites leading to delayed hypersensitivity
- Aromatic anticonvulsants (phenytoin, carbamazepine, lamotrigine) – Bioactivated to reactive intermediates, increasing SJS/TEN risk

Molecular Size and Immunogenicity:

- Large molecules (biologic drugs, monoclonal antibodies) – Directly activate immune responses
- Hapten-Carrier Concept – Small drugs (e.g., penicillins) act as haptens, binding to proteins and inducing an immune response

3.3 Patient-Specific Factors

Individual differences in age, medical history, and previous drug exposures influence hypersensitivity risk.

Age:

- Elderly patients – Increased risk due to altered drug metabolism and polypharmacy
- Children – Higher incidence of viral infection-associated hypersensitivity (e.g., amoxicillin in Epstein-Barr virus infections)

Comorbidities:

- Autoimmune diseases (e.g., lupus, rheumatoid arthritis) – Higher risk of hypersensitivity to biologics
- Viral infections (HIV, EBV, CMV) – Increased hypersensitivity risk with antibiotics and sulfa drugs

Previous Drug Exposure:

- Prior sensitization can lead to more severe reactions upon re-exposure (e.g., penicillin allergy)

3.4 Environmental Influences

Environmental factors can modulate immune responses and hypersensitivity risk.

Geographic and Ethnic Variability:

- HLA-associated hypersensitivity varies among ethnic groups (e.g., HLA-B*15:02 is common in Asian populations)

Infections and Immune System Activation:

- Viral infections can enhance immune reactivity, increasing hypersensitivity risk

Drug Interactions:

- Polypharmacy increases the likelihood of drug metabolism alterations and hypersensitivity reactions

IV. Common Drugs Causing Hypersensitivity Reactions

- Antibiotics (penicillins, sulfonamides)
- NSAIDs (aspirin, ibuprofen)
- Anticonvulsants (carbamazepine, phenytoin)
- Biologics & Monoclonal Antibodies
- Radiocontrast agents

V. DIAGNOSIS & CLINICAL PRESENTATION

The diagnosis of drug-induced hypersensitivity (DIH) is often challenging due to its diverse clinical manifestations and overlap with other conditions such as infections and autoimmune diseases. A systematic approach, including clinical evaluation, severity grading, and confirmatory diagnostic tests, is essential for accurate identification and management.

5.1 Symptoms & Severity Grading

DIH reactions range from mild skin eruptions to life-threatening systemic involvement. The clinical presentation varies depending on the mechanism of hypersensitivity (Type I–IV) and the specific drug involved.

5.1.1 Common Clinical Symptoms

- Cutaneous Reactions:
  - Maculopapular rash, urticaria, angioedema
  - Erythema multiforme, Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN)
- Respiratory Symptoms:
  - Wheezing, dyspnea, bronchospasm (Type I reactions)
- Gastrointestinal Symptoms:
  - Nausea, vomiting, diarrhea (common in anaphylaxis)
- Systemic Symptoms:
  - Anaphylaxis – Rapid-onset hypotension, tachycardia, loss of consciousness
  - Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) – Fever, lymphadenopathy, hepatitis, nephritis
  - Serum Sickness-Like Syndrome – Fever, rash, polyarthritis

5.1.2 Severity Grading

The severity of DIH reactions is graded based on clinical presentation:

Grade	Symptoms
Mild (Grade 1)	Localized rash, pruritus, mild urticaria
Moderate (Grade 2)	Widespread rash, fever, angioedema without systemic involvement
Severe (Grade 3)	Anaphylaxis, organ involvement (DRESS, SJS, TEN)
Life-Threatening (Grade 4)	Respiratory failure, shock, multiorgan failure

5.2 Diagnostic Tests

A combination of history-taking, laboratory tests, and confirmatory procedures is used to diagnose drug-induced hypersensitivity.

5.2.1 Skin Tests

- Used primarily for IgE-mediated (Type I) hypersensitivity reactions
- Types:
  - Skin Prick Test (SPT) – Detects immediate hypersensitivity to drugs like penicillin
  - Intradermal Test – More sensitive but carries a higher risk of systemic reactions
  - Patch Testing – Used for delayed hypersensitivity reactions (Type IV), such as contact dermatitis and DRESS
- Limitations: Not useful for severe cutaneous reactions (e.g., SJS/TEN)

5.2.2 In Vitro Assays

- Lymphocyte Transformation Test (LTT):
  - Detects T-cell-mediated drug hypersensitivity (Type IV reactions)
  - Useful for beta-lactams, anticonvulsants, and sulfonamides

- Serum Tryptase and Histamine Levels:
  - Elevated levels indicate mast cell degranulation in anaphylaxis
- Specific IgE Tests:
  - Identifies IgE-mediated hypersensitivity to drugs (e.g., penicillin)

5.2.3 Drug Provocation Tests (DPTs)

- Gold standard for confirming drug hypersensitivity when skin or in vitro tests are inconclusive
- Procedure:
  - Controlled oral, intravenous, or intradermal administration of the suspected drug
  - Conducted in a hospital setting with emergency support available
- Indications:
  - Used when history is unclear, and safer alternatives are unavailable
- Contraindications:
  - Severe reactions (anaphylaxis, SJS, TEN, DRESS)

VI. MANAGEMENT STRATEGIES

- Immediate management (epinephrine, antihistamines, corticosteroids)
- Drug withdrawal & alternative therapies
- Desensitization protocols
- Preventive approaches (genetic screening, patient counseling)

VII. CONCLUSION

Drug-induced hypersensitivity (DIH) represents a significant challenge in clinical practice, given its diverse immunological mechanisms, wide-ranging clinical presentations, and potential for severe, life-threatening reactions**.** Understanding the underlying mechanisms (Type I–IV hypersensitivity and non-immunologic pathways) is crucial for improving risk assessment and patient safety.

Several key risk factors**,** including genetic predisposition (HLA associations), drug properties, patient-specific characteristics, and environmental influences**,** contribute to DIH susceptibility. Advances in pharmacogenomics have provided valuable insights into genetic markers that can help predict hypersensitivity risks, such as HLA-B57:01 for abacavir and HLA-B**15**:02 for carbamazepine**.**

Early recognition and accurate diagnosis play a pivotal role in managing DIH. Clinical evaluation, severity grading, and confirmatory diagnostic tests (skin testing, in vitro assays, and drug provocation tests) are essential for distinguishing true hypersensitivity from non-allergic drug reactions. Personalized medicine approaches, such as genetic screening and immune-based assays**,** may enhance diagnostic precision and guide safer drug selection.

From a clinical management perspective**,** strategies such **as** drug desensitization, avoidance of cross-reactive drugs, and emergency preparedness for anaphylaxis are critical. Emerging research on biomarkers, novel immunomodulatory therapies, and AI-driven predictive models holds promise for improving patient outcomes in hypersensitivity reactions.

In conclusion, a multidisciplinary approach involving clinicians, immunologists, and pharmacologists is required to optimize the prevention, diagnosis, and management of drug-induced hypersensitivity**.** Continued research and technological advancements will further refine precision medicine strategies**,** ultimately reducing the burden of hypersensitivity-related adverse drug reactions.

REFERENCES

[1] Pichler, W. J. (2003). Drug hypersensitivity reactions: Classification and mechanisms. Journal of Allergy and Clinical Immunology, 111(5), S560-S566.

[2] Pichler, W. J. (2007). Delayed drug hypersensitivity reactions. Annals of Internal Medicine, 146(10), 680-691.

[3] Phillips, E. J., & Chung, W. H. (2015). Mechanisms of severe cutaneous adverse reactions to drugs. Current Allergy and Asthma Reports, 15(3), 5.

[4] Castells, M. (2020). Diagnosis and management of drug hypersensitivity reactions. Journal of Allergy and Clinical Immunology, 145(1), 142-149.

[5] Park, H. W., et al. (2011). Genetic factors in drug-induced hypersensitivity reactions. Allergy, Asthma & Immunology Research, 3(3), 173-179.

[6] White, K. D., et al. (2015). HLA and pharmacogenetic risk factors for drug hypersensitivity. Immunology and Allergy Clinics of North America, 35(2), 379-395.
[7] Yun, J., et al. (2019). Genetic susceptibility to drug-induced hypersensitivity reactions. Pharmacogenomics, 20(12), 883-897.
[8] Neugut, A. I., et al. (2001). The epidemiology of drug allergy. Pharmacology & Therapeutics, 90(2-3), 133-147.
[9] Bellón, T. (2019). Mechanisms of severe cutaneous adverse reactions to drugs. Biomedicine & Pharmacotherapy, 112, 108-602.
[10] Chung, W. H., et al. (2016). The role of T cells in drug hypersensitivity reactions. Allergy, 71(10), 1251-1260.
[11] Roujeau, J. C., & Stern, R. S. (1994). Severe adverse cutaneous reactions to drugs. New England Journal of Medicine, 331(19), 1272-1285.
[12] Pichler, W. J., et al. (2015). T-cell-mediated hypersensitivity reactions to drugs. International Archives of Allergy and Immunology, 168(3), 198-203.
[13] Cernadas, J. R., et al. (2010). Drug provocation tests: General considerations. Allergy, 65(3), 236-243.
[14] Doña, I., et al. (2012). In vitro diagnostic tests for drug hypersensitivity reactions. Current Opinion in Allergy and Clinical Immunology, 12(4), 297-304.
[15] Blumenthal, K. G., et al. (2019). The epidemiology of penicillin allergy. The Journal of Allergy and Clinical Immunology: In Practice, 7(6), 1802-1811.
[16] Romano, A., et al. (2011). Diagnosis and management of drug hypersensitivity reactions. Journal of Investigational Allergology and Clinical Immunology, 21(6), 446-457.
[17] Atanasković-Marković, M., et al. (2014). Challenges in diagnosing drug hypersensitivity in children. Pediatric Allergy and Immunology, 25(7), 723-731.
[18] Levine, B. B., & Zolov, D. M. (1984). The immune basis of allergic reactions to drugs. Annual Review of Pharmacology and Toxicology, 24(1), 121-141.
[19] Mockenhaupt, M. (2011). Severe cutaneous adverse drug reactions: Epidemiology and classification. Allergy, 66(6), 702-712.
[20] Scherer, K., et al. (2010). Mechanisms and management of drug hypersensitivity reactions. Allergology International, 59(3), 313-324.
[21] Cacoub, P., et al. (2011). Drug-induced hypersensitivity syndromes. Journal of Clinical Immunology, 31(5), 663-673.
[22] Demoly, P., et al. (2003). Advances in drug hypersensitivity diagnosis. Current Allergy and Asthma Reports, 3(1), 9-14.
[23] Bousquet, P. J., et al. (2009). Management of hypersensitivity reactions to beta-lactams. Allergy, 64(2), 183-193.
[24] Torres, M. J., et al. (2014). New insights into drug hypersensitivity mechanisms. The Journal of Allergy and Clinical Immunology, 134(3), 681-687.
[25] Gomes, E. R., & Demoly, P. (2005). Epidemiology of drug hypersensitivity. Current Opinion in Allergy and Clinical Immunology, 5(4), 309-316.
[26] Romano, A., et al. (2004). Diagnosis of nonimmediate reactions to beta-lactam antibiotics. The Journal of Allergy and Clinical Immunology, 113(5), 816-820.
[27] Macy, E., & Contreras, R. (2014). Health care use and serious infection prevalence associated with penicillin "allergy" in hospitalized patients. JAMA Internal Medicine, 174(9), 1341-1342.
[28] Doña, I., et al. (2019). Non-immediate hypersensitivity reactions to drugs. Immunology and Allergy Clinics of North America, 39(4), 501-515.
[29] Warrington, R. J., et al. (2011). Drug allergy: Immunopathology, diagnosis, and management. Allergy, Asthma & Clinical Immunology, 7(1), 9.
[30] Alfirevic, A., et al. (2014). Genomics of severe drug hypersensitivity reactions. Pharmacogenomics, 15(16), 2019-2032.
[31] White, K. D., et al. (2016). HLA and pharmacogenetic risk factors for drug hypersensitivity. Immunology and Allergy Clinics of North America, 36(4), 739-764.
[32] Cernadas, J., et al. (2013). Diagnosis and management of drug allergy. The Journal of Allergy and Clinical Immunology: In Practice, 1(1), 24-34.

[33] Mayorga, C., et al. (2016). Drug hypersensitivity: Advances in diagnosis and management. The Journal of Allergy and Clinical Immunology, 138(2), 420-434.
[34] Konvinse, K. C., et al. (2016). HLA associations with drug-induced hypersensitivity reactions. Annual Review of Medicine, 67, 13-27.